QLT, Inc.
VANCOUVER, CANADA—QLT Inc. today announced data from its CORE study, a Phase II trial being conducted by QLT’s wholly-owned subsidiary, QLT Plug Delivery, Inc. (QPD), to evaluate the safety and efficacy of its Latanoprost Punctal Plug Delivery System (L-PPDS) for the treatment of open angle glaucoma (OAG) and ocular hypertension (OH).